Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Investigating the link between clonal hematopoiesis and unprovoked pulmonary embolism

Official title: Is Clonal Hematopoiesis of Indeterminate Potential Associated With Unprovoked Pulmonary Embolism?

Run by Centre Hospitalier Universitaire, Amiens · NCT04711746 · Data updated 2026-11-12

This study is trying to see if a blood condition called clonal hematopoiesis is common in people who have had a sudden pulmonary embolism without any clear cause.

More Pulmonary Embolism trials

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment544 (estimated)
SponsorCentre Hospitalier Universitaire, Amiens
Academic / other
Locations1 site (Amiens)
StatusRecruiting
StartedFebruary 1, 2021
Main results expectedJanuary 2026
Study endsJanuary 2026
Registry record updatedMay 29, 2025
Trial IDNCT04711746 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals who have had a previous proximal unprovoked pulmonary embolism with negative thrombophilia screening.

Probably not a fit

Patients over 65 years old or those with active cancer may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the association between clonal hematopoiesis of indeterminate potential (CHIP) and unprovoked pulmonary embolism. It will involve analyzing blood samples from patients who have experienced unprovoked pulmonary embolism and comparing them to those with provoked pulmonary embolism. The research seeks to determine if CHIP is a frequent occurrence in these patients and whether it plays a role in the underlying mechanisms of the condition.

Why it matters

Potential benefit: If successful, this study could enhance understanding of the risk factors for unprovoked pulmonary embolism and lead to improved prevention strategies.

How similar studies have gone: While the investigation of CHIP in relation to pulmonary embolism is a novel approach, previous studies have linked CHIP to other vascular conditions, suggesting potential for meaningful insights.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* For cases : Previous proximal unprovoked pulmonary embolism, negative thrombophilia screening.
* For control : Previous proximal provoked pulmonary embolism, negative thrombophilia screening.

Exclusion Criteria:

* Age superior to 65 years old,
* Active cancer

Where it's running

  • CHU Amiens
    Amiens, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.